nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GRIA3—medulla oblongata—meningioma	0.0166	0.105	CbGeAlD
Lithium—GRIA3—spinal cord—meningioma	0.0148	0.0939	CbGeAlD
Lithium—GSK3B—medulla oblongata—meningioma	0.0144	0.0912	CbGeAlD
Lithium—GSK3B—spinal cord—meningioma	0.0128	0.0813	CbGeAlD
Lithium—GSK3A—medulla oblongata—meningioma	0.0125	0.0793	CbGeAlD
Lithium—GRIA3—cerebellum—meningioma	0.0117	0.0745	CbGeAlD
Lithium—IMPA1—brain—meningioma	0.0112	0.0712	CbGeAlD
Lithium—GSK3A—spinal cord—meningioma	0.0111	0.0707	CbGeAlD
Lithium—GSK3B—cerebellum—meningioma	0.0101	0.0645	CbGeAlD
Lithium—GRIA3—brain—meningioma	0.00952	0.0605	CbGeAlD
Lithium—GSK3A—cerebellum—meningioma	0.00882	0.0561	CbGeAlD
Lithium—IMPA2—brain—meningioma	0.0084	0.0534	CbGeAlD
Lithium—GSK3B—brain—meningioma	0.00824	0.0524	CbGeAlD
Lithium—GSK3A—brain—meningioma	0.00717	0.0456	CbGeAlD
Lithium—GSK3B—Signaling by FGFR in disease—PDGFB—meningioma	0.00243	0.00288	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—PDGFB—meningioma	0.00243	0.00288	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—PDGFB—meningioma	0.00241	0.00286	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—PTEN—meningioma	0.00241	0.00285	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—ERBB2—meningioma	0.0024	0.00285	CbGpPWpGaD
Lithium—GSK3B—Integrin-linked kinase signaling—AKT1—meningioma	0.00239	0.00284	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—PDGFB—meningioma	0.00239	0.00283	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—ERBB2—meningioma	0.00238	0.00282	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—PDGFB—meningioma	0.00237	0.00282	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—ERBB2—meningioma	0.00236	0.00281	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—ERBB2—meningioma	0.00235	0.00279	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—ERBB2—meningioma	0.00234	0.00278	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—TSHB—meningioma	0.00234	0.00278	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00231	0.00274	CbGpPWpGaD
Lithium—GSK3A—SREBP signalling—AKT1—meningioma	0.0023	0.00273	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—PDGFB—meningioma	0.00229	0.00272	CbGpPWpGaD
Lithium—GSK3A—Disease—AP1B1—meningioma	0.00229	0.00272	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—TP53—meningioma	0.00228	0.00271	CbGpPWpGaD
Lithium—GSK3B—Hedgehog signaling events mediated by Gli proteins—AKT1—meningioma	0.00227	0.0027	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—PTEN—meningioma	0.00225	0.00267	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PDGFB—meningioma	0.00225	0.00267	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PDGFB—meningioma	0.00224	0.00266	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—PTEN—meningioma	0.00223	0.00264	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—ERBB2—meningioma	0.0022	0.00261	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—ERBB2—meningioma	0.0022	0.00261	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.0022	0.00261	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—ERBB2—meningioma	0.00218	0.00259	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—PTEN—meningioma	0.00217	0.00258	CbGpPWpGaD
Lithium—GSK3B—Signaling events mediated by Stem cell factor receptor (c-Kit)—AKT1—meningioma	0.00216	0.00257	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—ERBB2—meningioma	0.00216	0.00257	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—PTEN—meningioma	0.00216	0.00256	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—PTEN—meningioma	0.00216	0.00256	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—ERBB2—meningioma	0.00215	0.00256	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—AKT1—meningioma	0.00215	0.00255	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PDGFB—meningioma	0.00215	0.00255	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—PTEN—meningioma	0.00213	0.00253	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway Netpath—AKT1—meningioma	0.00213	0.00253	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—AKT1—meningioma	0.00213	0.00253	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—PTEN—meningioma	0.00212	0.00252	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—PTEN—meningioma	0.00211	0.0025	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—PTEN—meningioma	0.00211	0.0025	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.00207	0.00246	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—PTEN—meningioma	0.00205	0.00243	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD34—meningioma	0.00204	0.00243	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—ERBB2—meningioma	0.00204	0.00242	CbGpPWpGaD
Lithium—GSK3B—Cardiac Hypertrophic Response—AKT1—meningioma	0.00204	0.00242	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—PTEN—meningioma	0.00204	0.00242	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTSL—meningioma	0.00203	0.00241	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—PTEN—meningioma	0.00203	0.0024	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—PTEN—meningioma	0.00202	0.00239	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—PTEN—meningioma	0.00201	0.00238	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—PTEN—meningioma	0.002	0.00237	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00197	0.00234	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—ERBB2—meningioma	0.00195	0.00232	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00195	0.00232	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CTSL—meningioma	0.00195	0.00231	CbGpPWpGaD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.00193	0.00229	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—AKT1—meningioma	0.00193	0.00229	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00188	0.00223	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—PTEN—meningioma	0.00188	0.00223	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—PTEN—meningioma	0.00188	0.00223	CbGpPWpGaD
Lithium—GSK3B—Notch Signaling Pathway—AKT1—meningioma	0.00188	0.00223	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—ERBB2—meningioma	0.00187	0.00222	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—PTEN—meningioma	0.00186	0.00221	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—PTEN—meningioma	0.00185	0.00219	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—ERBB2—meningioma	0.00184	0.00218	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—PTEN—meningioma	0.00184	0.00218	CbGpPWpGaD
Lithium—GSK3B—Immune System—AP1B1—meningioma	0.00184	0.00218	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—meningioma	0.00181	0.00214	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—AKT1—meningioma	0.0018	0.00214	CbGpPWpGaD
Lithium—GRIA3—BDNF signaling pathway—AKT1—meningioma	0.00178	0.00211	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.00177	0.0021	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—ERBB2—meningioma	0.00176	0.00208	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—meningioma	0.00175	0.00208	CbGpPWpGaD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—AKT1—meningioma	0.00175	0.00208	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—ERBB2—meningioma	0.00175	0.00207	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—ERBB2—meningioma	0.00174	0.00206	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—PTEN—meningioma	0.00174	0.00206	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—AKT1—meningioma	0.00174	0.00206	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—ERBB2—meningioma	0.00173	0.00205	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00171	0.00202	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—AKT1—meningioma	0.0017	0.00201	CbGpPWpGaD
Lithium—GSK3B—Disease—AP1B1—meningioma	0.0017	0.00201	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—AKT1—meningioma	0.00168	0.002	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD34—meningioma	0.00168	0.00199	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—PTEN—meningioma	0.00166	0.00198	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00166	0.00197	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PDGFB—meningioma	0.00165	0.00196	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.00164	0.00195	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—ERBB2—meningioma	0.00163	0.00193	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.00163	0.00193	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—ERBB2—meningioma	0.00163	0.00193	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—ERBB2—meningioma	0.00161	0.00191	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTSL—meningioma	0.0016	0.0019	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—ERBB2—meningioma	0.0016	0.0019	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—PTEN—meningioma	0.00159	0.00189	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—ERBB2—meningioma	0.00159	0.00189	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—AKT1—meningioma	0.00159	0.00189	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—PTEN—meningioma	0.00157	0.00186	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—PLAUR—meningioma	0.00154	0.00183	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—ERBB2—meningioma	0.00154	0.00183	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—ERBB2—meningioma	0.00151	0.00179	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—PTEN—meningioma	0.0015	0.00179	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—ERBB2—meningioma	0.0015	0.00178	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—PTEN—meningioma	0.0015	0.00178	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—PTEN—meningioma	0.00149	0.00177	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—PTEN—meningioma	0.00148	0.00176	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—AKT1—meningioma	0.00148	0.00176	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—PTEN—meningioma	0.00148	0.00175	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—meningioma	0.00147	0.00175	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—meningioma	0.00147	0.00175	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—meningioma	0.00146	0.00173	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00145	0.00173	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00145	0.00172	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00144	0.00171	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—meningioma	0.00144	0.00171	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.00143	0.00169	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—meningioma	0.0014	0.00166	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—PTEN—meningioma	0.00139	0.00165	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—PTEN—meningioma	0.00139	0.00165	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00139	0.00165	CbGpPWpGaD
Lithium—GSK3B—Androgen receptor signaling pathway—AKT1—meningioma	0.00139	0.00165	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—PTEN—meningioma	0.00138	0.00163	CbGpPWpGaD
Lithium—GSK3A—Disease—CST3—meningioma	0.00136	0.00162	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—PTEN—meningioma	0.00136	0.00162	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—PTEN—meningioma	0.00136	0.00161	CbGpPWpGaD
Lithium—GSK3B—Corticotropin-releasing hormone—AKT1—meningioma	0.00135	0.0016	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—PTEN—meningioma	0.00131	0.00156	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—AKT1—meningioma	0.0013	0.00154	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—AKT1—meningioma	0.00129	0.00154	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—PTEN—meningioma	0.00128	0.00152	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—AKT1—meningioma	0.00128	0.00152	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—PTEN—meningioma	0.00128	0.00152	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PDGFB—meningioma	0.00128	0.00152	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—PTEN—meningioma	0.00125	0.00149	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—AKT1—meningioma	0.00125	0.00149	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HES1—meningioma	0.00125	0.00148	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—AKT1—meningioma	0.00124	0.00148	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—AKT1—meningioma	0.00124	0.00147	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD34—meningioma	0.00124	0.00147	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00123	0.00146	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—AKT1—meningioma	0.00123	0.00146	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PDGFB—meningioma	0.00123	0.00146	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—AKT1—meningioma	0.00122	0.00145	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.00121	0.00144	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00121	0.00143	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTSL—meningioma	0.00118	0.0014	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—AKT1—meningioma	0.00118	0.0014	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—AKT1—meningioma	0.00117	0.00139	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—AKT1—meningioma	0.00117	0.00139	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—AKT1—meningioma	0.00116	0.00138	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—AKT1—meningioma	0.00116	0.00137	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—AKT1—meningioma	0.00115	0.00137	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.00113	0.00135	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB2—meningioma	0.00111	0.00132	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—AKT1—meningioma	0.00108	0.00128	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—AKT1—meningioma	0.00108	0.00128	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00108	0.00128	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—AKT1—meningioma	0.00107	0.00127	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—AKT1—meningioma	0.00106	0.00126	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—AKT1—meningioma	0.00106	0.00126	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.00102	0.00121	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TSHB—meningioma	0.00101	0.0012	CbGpPWpGaD
Lithium—GSK3B—Disease—CST3—meningioma	0.00101	0.0012	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ERBB2—meningioma	0.001	0.00119	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—AKT1—meningioma	0.001	0.00119	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTEN—meningioma	0.00098	0.00116	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—AKT1—meningioma	0.000959	0.00114	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.000959	0.00114	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—PTEN—meningioma	0.000946	0.00112	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PDGFB—meningioma	0.000944	0.00112	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—AKT1—meningioma	0.000943	0.00112	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—AKT1—meningioma	0.000918	0.00109	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PDGFB—meningioma	0.000906	0.00108	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—AKT1—meningioma	0.000904	0.00107	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTEN—meningioma	0.000873	0.00104	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—AKT1—meningioma	0.000867	0.00103	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—AKT1—meningioma	0.000863	0.00102	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—AKT1—meningioma	0.000859	0.00102	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMO—meningioma	0.000858	0.00102	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—meningioma	0.000856	0.00102	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—meningioma	0.000856	0.00102	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—AKT1—meningioma	0.000854	0.00101	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—AKT1—meningioma	0.00085	0.00101	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.000838	0.000994	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PGR—meningioma	0.000822	0.000976	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—meningioma	0.000822	0.000975	CbGpPWpGaD
Lithium—GSK3A—Disease—HES1—meningioma	0.000803	0.000953	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—AKT1—meningioma	0.0008	0.000949	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.0008	0.000949	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—AKT1—meningioma	0.0008	0.000949	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—AKT1—meningioma	0.000793	0.000941	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—AKT1—meningioma	0.000786	0.000932	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—AKT1—meningioma	0.000782	0.000928	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—meningioma	0.000756	0.000897	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TSHB—meningioma	0.000745	0.000885	CbGpPWpGaD
Lithium—GSK3A—Immune System—PDGFB—meningioma	0.000744	0.000883	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—meningioma	0.00074	0.000878	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—meningioma	0.000737	0.000875	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PTEN—meningioma	0.00073	0.000866	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—meningioma	0.000716	0.00085	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.000708	0.000841	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PTEN—meningioma	0.000701	0.000832	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—meningioma	0.000688	0.000816	CbGpPWpGaD
Lithium—GSK3A—Disease—PDGFB—meningioma	0.000687	0.000815	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—meningioma	0.000677	0.000804	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—meningioma	0.000656	0.000778	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMO—meningioma	0.000634	0.000752	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—meningioma	0.000632	0.00075	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—meningioma	0.000609	0.000722	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PGR—meningioma	0.000608	0.000721	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—meningioma	0.000607	0.000721	CbGpPWpGaD
Lithium—GSK3B—Disease—HES1—meningioma	0.000593	0.000704	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—meningioma	0.000565	0.00067	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HES1—meningioma	0.000562	0.000667	CbGpPWpGaD
Lithium—GSK3B—Immune System—PDGFB—meningioma	0.00055	0.000652	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—meningioma	0.000545	0.000647	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PTEN—meningioma	0.000539	0.00064	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PTEN—meningioma	0.000518	0.000615	CbGpPWpGaD
Lithium—GSK3B—Disease—PDGFB—meningioma	0.000507	0.000602	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—meningioma	0.000503	0.000597	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—meningioma	0.000502	0.000596	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—meningioma	0.000498	0.000592	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFB—meningioma	0.000481	0.000571	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—meningioma	0.00046	0.000546	CbGpPWpGaD
Lithium—GSK3A—Immune System—PTEN—meningioma	0.000425	0.000504	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—meningioma	0.000421	0.000499	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES1—meningioma	0.000415	0.000493	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—meningioma	0.000404	0.000479	CbGpPWpGaD
Lithium—GSK3A—Disease—PTEN—meningioma	0.000392	0.000466	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—meningioma	0.000368	0.000437	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFB—meningioma	0.000355	0.000422	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—meningioma	0.000352	0.000418	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—meningioma	0.00034	0.000404	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—meningioma	0.000322	0.000382	CbGpPWpGaD
Lithium—GSK3B—Immune System—PTEN—meningioma	0.000314	0.000373	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—meningioma	0.000311	0.000369	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—meningioma	0.000298	0.000354	CbGpPWpGaD
Lithium—GSK3B—Disease—PTEN—meningioma	0.00029	0.000344	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTEN—meningioma	0.000275	0.000326	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—meningioma	0.000245	0.000291	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—meningioma	0.000238	0.000283	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—meningioma	0.000226	0.000268	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTEN—meningioma	0.000203	0.000241	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—meningioma	0.000188	0.000223	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—meningioma	0.000181	0.000215	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—meningioma	0.000167	0.000198	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—meningioma	0.000158	0.000188	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—meningioma	0.000139	0.000164	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—meningioma	0.000117	0.000139	CbGpPWpGaD
